Biomarkers for determining the efficacy of immune checkpoint inhibitors
A method for identifying a patient with malignant tumor which can be expected to benefit more from an immune checkpoint inhibitor, and agent for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, being prescribed based thereon, comprising use of a combination of two sets of evaluation items and specific condition defined by each of combination thereof.
1 . A method for suppressing a progression of, suppressing a recurrence of and/or treating a malignant tumor, said method comprising:
(I) identifying a patient having any one of the conditions selected from the following items (a) to (c), wherein:
(a) is condition (a1) represented by formula:
Y 1 ≥a 1-1 ×X 1 +Y 1-1
wherein Y 1 represents a percentage (%) of CCR7 expressing cells among CD8 + T cells in a tumor tissue or blood from the patient with the malignant tumor prior to administration of an immune checkpoint inhibitor, a 1-1 represents about −637, X 1 represents a square root of a ratio of mean fluorescence intensity (MFI) of PD-1 expression in the CD8 + T cells to MFI of PD-1 expression in Foxp3 + T cells in the tumor tissue or blood from said patient, and Y 1-1 represents an arbitrary value from about 784 to about 914, or
condition (a2) represented by two formulas:
Y 1 ≤a 1-2 ×X 1 +Y 1-2 and Y 1 ≤a 1-3 ×X 1 +Y 1-3 ,
wherein Y 1 represents a percentage (%) of CCR7 expressing cells among the CD8 + T cells in the tumor tissue or blood from said patient, a 1-2 represents about −24.0, X 1 represents a square root of a ratio of MFI of PD-1 expression in the CD8 + T cells to MFI of PD-1 expression in the Foxp3 + T cells in the tumor tissue or blood from said patient, Y 1-2 represents an arbitrary value from about 39.0 to about 50.9, a 1-3 represents about 666, and Y 1-3 represents an arbitrary value from about −652 to about −522;
(b) is condition (b1) represented by formula:
Log 10 ( Y 3 +1)≥ a 3-1 ×X 3 +Y 3-1 or Log 10 ( Y 3 )≥ a 3-1 ×X 3 +Y 3-1 ,
wherein Y 3 represents a number of PD-1 expressing cells among the CD8 + T cells in the tumor tissue or blood from said patient, a 3-1 represents about −1.59, X 3 represents the square root of the ratio of MFI of PD-1 expression in the CD8 + T cells to MFI of PD-1 expression in the Foxp3 + T cells in the tumor tissue or blood from of said patient, and Y 3-1 represents an arbitrary value from about 4.09 to about 4.89, or
condition (b2) represented by formula:
Log 10 ( Y 3 +1)≥ a 3-2 ×X 3 +Y 3-2 or Log 10 ( Y 3 )≥ a 3-2 ×X 3 +Y 3-2 ,
wherein Y 3 represents a number of PD-1 expressing cells among the CD8 + T cells in the tumor tissue or blood from said patient, a 3-2 represents about −9.05, X 3 represents the square root of the ratio of MFI of PD-1 expression in the CD8 + T cells to MFI of PD-1 expression in the Foxp3 + T cells in the tumor tissue or blood from said patient, and Y 3-2 represents an arbitrary value from about 10.7 to about 13.3; and
(c) the condition is represented by formula:
a 8-1 ×X 8 +Y 8-1 ≤Y 8 ≤a 8-2 ×X 8 +Y 8-2 ,
wherein Y 8 represents a square root of a ratio of MFI of PD-1 expression in CD3 + cells to MFI of PD-1 expression in Fraction II Treg cells in the tumor tissue or blood from said patient, a 8-1 represents about −0.00338, X 8 represents a percentage (%) of PD-1 expressing cells among CD4 + T cells in the tumor tissue or blood from said patient, Y 8-1 represents an arbitrary value from about 0.939 to about 1.37, a 8-2 represents about 0.270, and Y 8-2 represents an arbitrary value from about −6.98 to about −0.654; and
(II) administering an effective dose of the immune checkpoint inhibitor to the patient identified in (I).
2 . The method according to claim 1 , wherein in (a) Y 1-1 represents 853, Y 1-2 represents 44.6, and Y 1-3 represents −591, in (b) Y 3-1 represents 4.42 and Y 3-2 represents 11.7, and in (c) Y 8-1 represents 1.17 and Y 8-2 represents −4.10.
3 . A method for suppressing a progression of, suppressing a recurrence of and/or treating a malignant tumor, said method comprising:
(I) identifying a patient having a following condition:
in a tumor tissue or blood from said patient prior to administration of an immune checkpoint inhibitor a combination of items (1) and (2) below:
(1) any one selected from items (i) to (v):
(i) a percentage (%) of PD-1 expressing cells among Fraction III Treg cells,
(ii) a percentage (%) of PD-1 expressing cells among Foxp3 + T cells,
(iii) a percentage (%) of PD-1 expressing cells among Fraction II Treg cells,
(iv) a square root of a ratio of MFI of PD-1 expression in CD8 + T cells to MFI of PD-1 expression in the Foxp3 + T cells, and
(v) a percentage (%) of PD-1 expressing cells among CD4 + T cells; and
(2) a percentage (%) of PD-1 expressing cells among the CD8 + T cells,
meets conditions selected from items (a) to (e), corresponding to items (i) to (v), respectively:
(a) condition represented by formula:
Y 2 ≥a 2-1 ×X 2 +Y 2-1 ,
wherein Y 2 represents the percentage (%) of item (i), a 2-1 represents about 0.765, X 2 represents the percentage (%) of item (2), and Y 2-1 represents an arbitrary value from about 50.6 to about 59.2, or formula:
Y 2 ≤a 2-2 ×X 2 +Y 2-2 ,
wherein Y 2 represents the percentage (%) of item (i), a 2-2 represents about 1.56, X 2 represents the percentage (%) of item (2), and Y 2-2 represents an arbitrary value from about −44.1 to about 14.5;
(b) condition represented by formula:
Y 5 ≥a 5 ×X 5 +Y 5-1 ,
wherein Y 5 represents the percentage (%) of item (ii), as represents about 2.34, X 5 represents the percentage (%) of item (2), and Y 5-1 represents an arbitrary value from about −117 to about 131;
(c) condition represented by formula:
Y 6 ≥a 6-1 ×X 6 +Y 6-1 ,
wherein Y 6 represents the percentage (%) of item (iii), a 6-1 represents about 1.69, X 6 represents the percentage (%) of item (2), and Y 6-1 represents an arbitrary value from about 21.4 to about 44.1, or formula:
Y 6 ≤a 6-2 ×X 6 +Y 6-2 ,
wherein Y 6 represents the percentage (%) of item (iii), a 6-2 represents about 1.78, X 6 represents the percentage (%) of item (2), and Y 6-2 represents an arbitrary value from about −80.6 to about −21.0;
(d) condition represented by formula:
Y 4 ≥a 4-1 ×X 4 +Y 4-1 ,
wherein Y 4 represents a square root of item (iv), a 4-1 represents about −0.00273, X 4 represents the percentage (%) of item (2), and Y 4-1 represents an arbitrary value from about 0.905 to about 1.46, or formula:
Y 4 ≥a 1-2 ×X 4 +Y 4-2 ,
wherein Y 4 represents the square root of item (iv), a 4-2 represents about −0.0294, X 4 represents the percentage (%) of item (2), and Y 4-2 represents an arbitrary value from about 2.18 to about 3.31; and
(e) condition represented by formula:
Y 7 ≤a 7-1 ×X 7 +Y 7-1 ,
wherein Y 7 represents the percentage (%) of item (v), a 7-1 represents about 0.227, X 7 represents the percentage (%) of item (2), and Y 7-1 represents an arbitrary value from about −13.9 to about 4.03, or formula:
Y 7 ≤a 7-2 ×X 7 +Y 7-2 ,
wherein Y 7 represents the percentage (%) of item (v), a 7-2 represents about 3.32, X 7 represents the percentage (%) of item (2), and Y 7-2 represents an arbitrary value from about −199 to about 58.2; and
(II) administering an effective dose of the immune checkpoint inhibitor to the patient identified in (I).
4 . The method according to claim 3 , wherein in (a) Y 2-1 represents 54.1 and Y 2-2 represents −26.6, in (b) Y 5-1 represents −54.4, in (c) Y 6-1 represents 31.8 and Y 6-2 represents −48.2, in (d) Y 4-1 represents 1.18 and Y 4-2 represents 2.74, and in (e) Y 7-1 represents −6.56 and Y 7-2 represents −93.5.
5 . The method according to claim 3 , wherein an active ingredient of the immune checkpoint inhibitor is an anti-PD-1 antibody, anti-PD-L1 antibody, PD-1 antagonist, PD-L1/VISTA antagonist, PD-L1/TIM3 antagonist, anti-PD-L2 antibody, PD-L1 fusion protein, PD-L2 fusion protein, anti-CTLA-4 antibody, anti-LAG-3 antibody, LAG-3 fusion protein, anti-Tim3 antibody, anti-KIR antibody, anti-BTLA antibody, anti-TIGIT antibody, anti-VISTA antibody, anti-CSF-1R antibody or CSF-1R inhibitor.
6 . The method according to claim 5 , wherein the anti-PD-1 antibody is Nivolumab, Cemiplimab, Pembrolizumab, Spartalizumab, Tislelizumab, Dostarlimab, Toripalimab, Camrelizumab, Genolimzumab, Sintilimab, Lodapolimab, Retifanlimab, Balstilimab, Serplulimab, Budigalimab, Prolgolimab, Sasanlimab, Cetrelimab, Zimberelimab, Penpulimab, AMP-514, STI-A1110, ENUM 388D4, ENUM 244C8, GLS010, CS1003, BAT-1306, AK103, BI 754091, LZM009, CMAB819, Sym021, SSI-361, JY034, HX008, ISU106 or CX-188.
7 . The method according to claim 5 , wherein the anti-PD-L1 antibody is Atezolizumab, Avelumab, Durvalumab, Manelimab, Pacmilimab, Envafolimab, Cosibelimab, BMS-936559, STI-1014, HLX20, SHR-1316, CS1001, MSB2311, BGB-A333, KL-A167, AK106, AK104, ZKAB001, FAZ053, CBT-502 or JS003.
8 . The method according to claim 5 , wherein the anti-CTLA-4 antibody is Ipilimumab, Zalifrelimab, Nurulimab or Tremelimumab.
9 . The method according to claim 5 , wherein the malignant tumor is a solid cancer or a hematological cancer.
10 . The method according to claim 9 , wherein the solid cancer is one or more cancers selected from malignant melanoma, non-small cell lung cancer, small cell lung cancer, head and neck cancer, renal cell carcinoma, clear cell renal cell carcinoma, breast cancer, ovarian cancer, serous ovarian cancer, ovarian clear cell adenocarcinomas, nasopharyngeal cancer, uterine cancer, anal cancer, colorectal cancer, rectum cancer, colon cancer, hepatocellular carcinoma, esophageal cancer, esophageal adenocarcinoma, gastric cancer, esophagogastric junction cancer, small intestine cancer, pancreatic cancer, urothelial cancer, prostate cancer, fallopian tube cancer, primary peritoneal cancer, malignant pleural mesothelioma, gallbladder cancer, bile duct cancer, biliary tract cancer, skin cancer, testicular cancer, vaginal cancer, vulvar cancer, penile cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, spinal tumor, brain tumor, squamous cell carcinoma, bone/soft tissue sarcomas and Kaposi's sarcoma.
11 . The method according to claim 3 , wherein the patient with a malignant tumor has no history of treatment with other anti-neoplastic drugs.
12 . The method according to claim 3 , wherein a percentage (%) of PD-L1 expressing tumor cells among tumor cells in the malignant tumor tissue (TPS) or a total percentage (%) of PD-L1 positive tumor cells, lymphocytes and macrophages among tumor cells in the malignant tumor tissue (CPS) is less than 50%.
13 . The method according to claim 3 , wherein the malignant tumor is a malignant tumor without high-frequency microsatellite instability (MSI-H) and/or deficient mismatch repair (dMMR).
14 . The method according to claim 3 , wherein a tumor mutation burden (TMB) of the malignant tumor is low frequency.